VTAK News & Events

Catheter Precision announced balance sheet improvements through new institutional capital commitments supporting the Company's next phase of growth. Fly Flyte, a newly acquired subsidiary of VTAK, is now positioned to execute its expansion strategy with a fully funded growth plan supported by its parent company, Catheter Precision. VTAK has recently completed multiple strategic financings designed to support the Company's transformation and the expansion of the Flyte aviation platform. The financing also provides capital to fund the Company's medical device operations. The Company's recent capital initiatives are expected to support the continued expansion of the Flyte platform and the Company's broader operational transformation. Capital intended to support: Fleet expansion and aircraft acquisitions Market expansion across additional regional corridors Scaling Flyte's aviation platform infrastructure Balance sheet simplification Reduction of legacy liabilities Management believes these initiatives position the Company as a more streamlined public company with significant exposure to the rapidly expanding regional aviation market.

Creatd, Inc. (CRTD) has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, to Catheter Precision (VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Creatd as a significant shareholder in VTAK. The NYSE-listed VTAK equity becomes part of Creatd's growing portfolio of public and private positions across diversified industries, supported by its technology and AI-first operational infrastructure. Creatd helps companies overcome structural hurdles and mature into institutionally viable enterprises. Creatd acquired Flyte approximately one year ago, after initiating due diligence in Q4 2024, and implemented a disciplined turnaround strategy built around operational optimization, technology integration, and targeted revenue growth, while positioning the company for acquisition by a nationally-listed platform. Creatd initially acquired its position in Flyte using a combination of financing and its then OTC Pink Sheet common stock, whereas the premium exit consideration consists of cash and preferred equity in a New York Stock Exchange-listed company.

Catheter Precision(VTAK) announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte from Creatd, Inc. (CRTD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure, and scalable fleet economics. Flyte operates under FAA 14 CFR Part 135 certification, deploying Cirrus Vision Jets across high-frequency, short-haul regional routes where commercial airline capacity remains constrained or does not exist. The business currently generates revenue through the operation of aircraft equipped with advanced integrated safety systems, including whole-aircraft parachute technology and Safe Return autonomous landing capability. With full ownership now complete, all Flyte operations, assets, and economics are fully consolidated within VTAK, providing direct exposure to operating performance and long-term equity value creation. Going forward, Flyte's financial results will be consolidated into VTAK's financial statements.